Urinary and glomerular podocytes in patients with chronic kidney diseases

Clinical and Experimental Nephrology

Volumn 18, Issue 1, 2014, Pages 95-103

  Hanamura, Kikuno ^a   Tojo, Akihiro ^a   Fujita, Toshiro ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Glomerulosclerosis; Oxidative stress; Proteinuria; Renal pathology; Urinary podocyte

Indexed keywords

ALBUMIN; DICHLORODIHYDROFLUORESCEIN DIACETATE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PEROXIDE; PODOCALYXIN; REACTIVE OXYGEN METABOLITE; BIOLOGICAL MARKER;

ACUTE GLOMERULONEPHRITIS; ADOLESCENT; ADULT; AGED; ALPORT SYNDROME; ARTICLE; CELL INFILTRATION; CELL LOSS; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIABETIC NEPHROPATHY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GEL ELECTROPHORESIS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATORY CELL; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROSCLEROSIS; PODOCYTE; PROTEIN URINE LEVEL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RISK FACTOR; URINARY EXCRETION; YOUNG ADULT; AGE; ALBUMINURIA; BIOPSY; CHRONIC KIDNEY FAILURE; CYTOLOGY; METABOLISM; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; URINE; VERY ELDERLY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALBUMINURIA; BIOMARKERS; BIOPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEROXIDES; PODOCYTES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; URINE; YOUNG ADULT;

EID: 84896703460     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0814-8     Document Type: Article

References (41)

1. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol. 2002;13:3005-15.
2. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99:342-8.
3. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, Myers BD. Podocytopenia and disease severity in IgA nephropathy. Kidney Int. 2002;61:1475-85.
4. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int. 2005;67:404-19.
5. Shankland SJ. The podocyte's response to injury. Role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69:2131-47.
6. Steffes MW, Schmidt D, McCrery R, Basgen JM, International Diabetic Nephropathy Study Group. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 2001;59:2104-13.
7. Hara M, Yamamoto T, Yanagihara T, Takada T, Itoh M, Adachi Y, Yoshizumi A, Kawasaki K, Kihara I. Urinary excretion of podocalyxin indicates glomerular epithelial cell injuries in glomerulonephritis. Nephron. 1995;69:397-403.
8. Hara M, Yanagihara T, Takada T, Itoh M, Matsuno M, Yamamoto T, Kihara I. Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol. 1998;18:35-41.
9. Kanno K, Kawachi H, Uchida Y, Hara M, Shimizu F, Uchiyama M. Urinary sediment podocalyxin in children with glomerular diseases. Nephron Clin Pract. 2003;95:c91-9.
10. Hara M, Yanagihara T, Kihara I, Higashi K, Fujimoto K, Kajita T. Apical cell membranes are shed into urine from injured podocytes. A novel phenomenon of podocyte injury. J Am Soc Nephrol. 2005;16:408-16.
11. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol. 2000;20:373-9.
12. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H. Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci. 2000;320:112-6.
13. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 2000;15:1379-83.
14. Hara M, Yanagihara T, Kihara I. Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron. 2001;89:342-7.
15. Hara M, Yamagata K, Tomino Y, Saito A, Hirayama Y, Ogasawara S, Kurosawa H, Sekine S, Yan K. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia. 2012;55(11):2913-9.
16. Wang Y, Zhao S, Loyd S, Groome LJ. Increased urinary excretion of nephrin, podocalyxin, and βig-h3 in women with preeclampsia. Am J Physiol Renal Physiol. 2012;302(9):F1084-9.
17. Asao R, Asanuma K, Kodama F, Akiba-Takagi M, Nagai-Hosoe Y, Seki T, Takeda Y, Ohsawa I, Mano S, Matsuoka K, Kurosawa H, Ogasawara S, Hirayama Y, Sekine S, Horikoshi S, Hara M, Tomino Y. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol. 2012;7(9):1385-93.
18. Szeto CC, Lai KB, Chow KM, Szeto CY, Yip TW, Woo KS, Li PK, Lai FM. Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric diseases. Clin Chim Acta. 2005;361:182-90.
19. Sato Y, Wharram BL, Lee SK, Wickman L, Goyal M, Venkatareddy M, Chang JW, Wiggins JE, Lienczewski C, Kretzler M, Wiggins RC. Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol. 2009;20:1041-52.
20. Fukuda A, Wickman LT, Venkatareddy MP, Wang SQ, Chowdhury MA, Wiggins JE, Shedden KA, Wiggins RC. Urine podocin:nephrin mRNA ratio (PNR) as a podocyte stress biomarker. Nephrol Dial Transplant. 2012;27(11):4079-87.
21. Ding G, Reddy K, Kapasi AA, Franki N, Gibbons N, Kasinath BS, Singhal PC. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol. 2002;283:F173-80.
22. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 2004;65:30-9.
23. Neale TJ, Ojha PP, Exner M, Poczewski H, Rüger B, Witztum JL, Davis P, Kerjaschki D. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J Clin Invest. 1994;94:1577-84.
24. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy. Effects of ACEI and ARB. Kidney Int. 2002;61:186-94.
25. Vega-Warner V, Ransom RF, Vincent AM, Brosius FC, Smoyer WE. Induction of antioxidant enzymes in murine podocytes precedes injury by puromycin aminonucleoside. Kidney Int. 2004;66:1881-9.
26. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int. 1992;42:148-60.
27. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ, Wilcox CS. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension. 2002;39:269-74.
28. Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T. Angiotensin II and oxidative stress in Dahl salt-sensitive rat with heart failure. Hypertension. 2002;40:834-9.
29. Asaba K, Tojo A, Onozato ML, Goto A, Quinn MT, Fujita T, Wilcox CS. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int. 2005;67:1890-8.
30. Tojo A, Asaba K, Onozato ML. Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opin Ther Targets. 2007;11:1011-8.
31. Kinugasa S, Tojo A, Sakai T, Tsumura H, Takahashi M, Hirata Y, Fujita T. Selective albuminuria via podocyte albumin transport in puromycin nephrotic rats is attenuated by an inhibitor of NADPH oxidase. Kidney Int. 2011;80:1328-38.
32. Hara M, Yanagihara T, Kihara I. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schönlein-Henoch purpura nephritis. Clin J Am Soc Nephrol. 2007;2:231-8.
33. Asaba K, Tojo A, Onozato ML, Kinugasa S, Miyazaki H, Miyashita K, Uehara Y, Hirata Y, Kimura K, Goto A, Omata M, Fujita T. Long-term renal prognosis of IgA nephropathy with therapeutic trend shifts. Intern Med. 2009;48:883-90.
34. Kriz W, Hosser H, Hahnel B, Gretz N, Provoost AP. From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: a histopathological study in rat models and human glomerulopathies. Nephrol Dial Transplant. 1998;13:2781-98.
35. Bazzi C, Petrini C, Rizza V, Arrigo G, D'Amico G. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int. 2000;58:1732-41.
36. Woo KT, Lau YK, Yap HK, Lee GS, Chiang GS, Lim CH. Protein selectivity: a prognostic index in IgA nephritis. Nephron. 1989;52:300-6.
37. Bazzi C, Petrini C, Rizza V, Arrigo G, Beltrame A, Pisano L, D'Amico G. Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am J Kidney Dis. 2001;38:240-8.
38. Tojo A, Endou H. Intrarenal handling of proteins in rats using fractional micropuncture technique. Am J Physiol. 1992;263:F601-6.
39. Deen WM. What determines glomerular capillary permeability? J Clin Invest. 2004;114:1412-4.
40. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003;63:809-25.
41. Blouch K, Deen WM, Fauvel JP, Bialek J, Derby G, Myers BD. Molecular configuration and glomerular size selectivity in healthy and nephrotic humans. Am J Physiol. 1997;273:F430-7.